Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Deodhar

Showing results (151-160 of 272) with videos related to

Pageof 28
Sort By:
ACR Open Rheumatology|September 22, 2021
The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan DatabasesJeffrey R Curtis, Kevin Winthrop, Rhonda L Bohn, et al.
Rheumatology and Therapy|January 20, 2026
Patients' Perspectives Regarding Ankylosing Spondylitis Treatment Administration Features: Evidence from Qualitative Interviews and a Multinational Quantitative Preference SurveyAtul Deodhar, Martine C Maculaitis, Lewis Kopenhafer, et al.
Annals of the Rheumatic Diseases|May 7, 2013
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trialJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Arthritis Care & Research|November 23, 2020
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled TrialsTore K Kvien, Philip G Conaghan, Laure Gossec, et al.
The Journal of Rheumatology|March 3, 2019
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
Arthritis and Rheumatism|September 2, 2008
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year periodJürgen Braun, Atul Deodhar, Ben Dijkmans, et al.
The Journal of Rheumatology|April 1, 2026
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
The New England Journal of Medicine|December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisDominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Clinical Rheumatology|August 16, 2020
Assessing rheumatologists' attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effortNeha Rich-Garg, Abhijeet Danve, Dongseok Choi, et al.
Rheumatology and Therapy|September 30, 2022
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative ReviewIrene E van der Horst-Bruinsma, Philip C Robinson, Ennio G Favalli, et al.
Pageof 28

Showing results (151-160 of 272) with videos related to

Sort By:
Pageof 28
ACR Open Rheumatology|September 22, 2021
The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan DatabasesJeffrey R Curtis, Kevin Winthrop, Rhonda L Bohn, et al.
Rheumatology and Therapy|January 20, 2026
Patients' Perspectives Regarding Ankylosing Spondylitis Treatment Administration Features: Evidence from Qualitative Interviews and a Multinational Quantitative Preference SurveyAtul Deodhar, Martine C Maculaitis, Lewis Kopenhafer, et al.
Annals of the Rheumatic Diseases|May 7, 2013
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trialJürgen Braun, Xenofon Baraliakos, Kay-Geert A Hermann, et al.
Arthritis Care & Research|November 23, 2020
Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled TrialsTore K Kvien, Philip G Conaghan, Laure Gossec, et al.
The Journal of Rheumatology|March 3, 2019
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
Arthritis and Rheumatism|September 2, 2008
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year periodJürgen Braun, Atul Deodhar, Ben Dijkmans, et al.
The Journal of Rheumatology|April 1, 2026
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE StudyJohn D Reveille, Atul Deodhar, Paul H Caldron, et al.
The New England Journal of Medicine|December 25, 2015
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing SpondylitisDominique Baeten, Joachim Sieper, Jürgen Braun, et al.
Clinical Rheumatology|August 16, 2020
Assessing rheumatologists' attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effortNeha Rich-Garg, Abhijeet Danve, Dongseok Choi, et al.
Rheumatology and Therapy|September 30, 2022
Certolizumab Pegol Treatment in Patients with Axial-Spondyloarthritis-Associated Acute Anterior Uveitis: a Narrative ReviewIrene E van der Horst-Bruinsma, Philip C Robinson, Ennio G Favalli, et al.
Pageof 28